Brandon J. Essink , Wim Vermeulen , Coralie Andrade , Richard de Rooij , Leah Isakov , Daniela Casula , Frank R. Albano
{"title":"疫苗51(2025)126791:50岁及以上成人中mf59佐剂四价亚单位灭活细胞衍生流感疫苗(aQIVc)的随机2期免疫原性和安全性研究的更正","authors":"Brandon J. Essink , Wim Vermeulen , Coralie Andrade , Richard de Rooij , Leah Isakov , Daniela Casula , Frank R. Albano","doi":"10.1016/j.vaccine.2025.127127","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"56 ","pages":"Article 127127"},"PeriodicalIF":4.5000,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Corrigendum to ‘A randomised phase 2 immunogenicity and safety study of a MF59-adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine (aQIVc) in adults aged 50 years and older’ Vaccine 51 (2025) 126791\",\"authors\":\"Brandon J. Essink , Wim Vermeulen , Coralie Andrade , Richard de Rooij , Leah Isakov , Daniela Casula , Frank R. Albano\",\"doi\":\"10.1016/j.vaccine.2025.127127\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":23491,\"journal\":{\"name\":\"Vaccine\",\"volume\":\"56 \",\"pages\":\"Article 127127\"},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2025-05-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Vaccine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0264410X25004244\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/4/25 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0264410X25004244","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/25 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
Corrigendum to ‘A randomised phase 2 immunogenicity and safety study of a MF59-adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine (aQIVc) in adults aged 50 years and older’ Vaccine 51 (2025) 126791
期刊介绍:
Vaccine is unique in publishing the highest quality science across all disciplines relevant to the field of vaccinology - all original article submissions across basic and clinical research, vaccine manufacturing, history, public policy, behavioral science and ethics, social sciences, safety, and many other related areas are welcomed. The submission categories as given in the Guide for Authors indicate where we receive the most papers. Papers outside these major areas are also welcome and authors are encouraged to contact us with specific questions.